Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Be sure to catch the early registration break for 2024 RheumNow Live
Palmoplantar pustulosis (PPP) is difficult to treat; w/ few reports of JAKi efficacy. Now
ACR Convergence is truly drinking from the proverbial fire hose. It’s a beautiful mash-up of basic science and treatment updates meets guidelines, recommendations, and disease identification. My goal when attending any conference is to learn as much as I can, synthesize that information, and
Read Article
Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting.
2023 Medscaped Female Compensation Survey asked What percentage would again chose their specialty ? Top 5
A JAMA systematic review and meta-analysis has showed the use of JAK inhibitors (JAKi) in immune-mediated inflammatory skin diseases was not associated with increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE) (compared to the
Read Article
Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.
Read Article
EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.
A multinational international Task Force included 35 rheumatologists, five
Read Article
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.
Full Read review of #PMR in Lancet: - Start @ 12·5–25mg prednisone qd - Remission in most but, relapses in 40–60% - Onset sudden; AM stiffness predominates;
While comorbidities, including an increased cardiovascular (CV) risk, are associated with severe psoriasis, less is known about subclinical CV disease and when it occurs in patients with psoriasis.
Coronary microvascular dysfunction (CMD) has been shown to be predictive of future
Read Article
Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions.
UCB has issued a press update on its pending application for the approval of their
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".
Read Article
Systemic sclerosis (SSc) sine scleroderma is a unique and rare subset of SSc defined by the absence of skin fibrosis. An analysis of the EUSTAR database suggests systemic disease can be a problem, including interstitial lung disease (>40%) and SSc renal crisis (almost 3%).
Read Article
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.
Glucocorticoid Affects Weight, but not Blood Pressure in RA A pooled analysis of 5 RCTs shows that the effects of 2 years of low-dose glucocorticoid (GC) treatment in RA can significantly
Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:
Swedish study of 325 #AAV pts saw CVA in 35 pts (8%); CVA incidence=11.3/1000 PYs - this was higher than gen population [SIR 1.85). AAV CVA risk factors included age
In research published in Arthritis & Rheumatology, investigators developed and validated a tool called PRESTO that
Read Article
Links:
IL-23 inhibitors are approved for the treatment of psoriasis and psoriatic arthritis; a single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA.
Read Article
Links:
More than eight million people in the U.S. experience psoriasis, a condition in which skin cells build up and form itchy dry patches. A person’s vitamin D levels could play an important role in psoriasis severity, according to one of the largest studies to date.
The analysis, which
Read Article
Links:
The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest. People typically have psoriatic skin disease for a decade or more before they begin to experience the joint involvement of PsA. Understanding more about the natural
Read Article
With their publication in June 2022 (1), the 3rd iteration of the Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment recommendations for Psoriatic Arthritis (PsA) may have set a record or sorts.
Read Post
